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Abstract 
 
Objective or Hypothesis : The purpose of this study was to determine craving and withdrawal symptomatology by 
menstrual phase during acute smoking abstinence in women on a combination birth control pill (BCP; Tri-Sprintec) with 
steady hormonal levels compared to women not on birth control pills (no-BCP) with fluctuating cyclic hormonal levels.  
We hypothesized that the BCP women would experience different levels of symptomatology (including craving, 
withdrawal, smoking urges, and depression) than the no-BCP women and that the BCP women would experience less 
menstrual cycle variation in symptomatology than the no-BCP women. 
 
Population : Women (n=42) aged 18-40 who smoked >5 cigarettes/day and experienced regular menstrual cycles were 
enrolled in a larger controlled cross-over study. Participants in this study were 27.1+6.3 years old and smoked an average 
of 10.4 cigarettes/day. The BCP group was significantly younger than the no-BCP group (23.4+4.7 vs. 29.0+6.2, p=0.005, 
respectively); therefore subsequent analyses controlled for age. Groups were matched on depressive symptoms, menstrual 
phase, race, and time to first morning cigarette. 
 
Methods Participants quit smoking for two four-day periods: once during Week 1 (e.g. Follicular (F) phase/1st week of 
Tri-Sprintec) and Week 3 (e.g. Luteal (L) phase/3rd week of Tri-Sprintec).  Participants completed daily questionnaires 
(the Minnesota Nicotine Withdrawal Scale (MNWS), the Questionnaire of Smoking Urges-Brief (QSU), and the Center 
for Epidemiologic Studies Depression Scale (CES-D)) to assess symptomatology. Participants then returned to ad libitum 
smoking for approximately 6 weeks before completing identical procedures in the alternate menstrual phase/week of BCP. 
Phase variation was calculated by subtracting Follicular scores from Luteal scores (L-F). Analyses included logistic 
regression and growth curve models using SAS 9.2. 
 
Main Results On quit day, BCP women reported greater withdrawal symptomatology in Week 1 while no-BCP women 
reported greater symptomatology during Week 3  (-2.00+6.54 vs. 1.77+5.76, p=0.03). On the third day of abstinence, BCP 
women reported more depressive symptoms in Week 1 while no-BCP women reported more depressive symptoms in 
Week 3 (-1.45+5.22 vs. 3.56+9.90, p=0.05). On the fourth day of abstinence, BCP women scored higher on QSU Factor 2 
(Relief of Negative Affect) during Week 3 whereas no-BCP women scored higher in Week 1 (2.67+4.72 vs. -1.61+5.76, 
p=0.05). No other significant differences were found.      
 
Conclusions These results suggest that ovarian hormones affect smoking-related symptomatology in both naturally 
cycling women and women on BCPs.  Additional work is needed to examine how this may affect smoking cessation 
efforts.   
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